OncoCyte

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OncoCyte Corporation (NASDAQ:OCX ) Q3 2024 Results Conference Call November 12, 2024 5:00 PM ET Company Participants Julie Silber - PCG Advisory Josh Riggs - President and CEO Andrea James - CFO Ekke Schutz - Chief Science Officer Conference Call Participants Joseph Conway - Needham Vidyun Bais - BTIG Operator Thank you for standing by. My name is Kayla, and I will be your conference operator today.

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes.

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

IRVINE, Calif., Oct. 16, 2024 – PRISM MediaWire –  Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles.

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles.

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

FrontView REIT Inc

GATX

GRAIL Inc

Cartesian Therapeutics Inc

24/7 Wall St. Insights Insider buying slowed to a trickle ahead of the third-quarter earnings reporting season.

Insider Buying Slows, but Not for 7 These Buyers

IRVINE, Calif., October 8, 2024 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its proprietary gene expression test, DetermaIO™.

Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Bio-Rad Laboratories

IRVINE, Calif., Oct. 02, 2024 – PRISM MediaWire – Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that its new customers include two leading transplant university hospitals in the U.S. and Germany.

Oncocyte Signs Leading Transplant Centers in US and Germany

Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories IRVINE, Calif., Oct. 02, 2024 – Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with new and existing investors, including Bio-Rad Laboratories, Inc.

Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

Case Series represents second study showing VitaGraft Kidney as a measure of response to the benefit of therapy for one leading cause of allograft failure IRVINE, Calif., August 12, 2024 — Oncocyte Corp.

Oncocyte's VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Interest in kidney transplant assay represents approximately 25% of US transplant volume Company lays out land and expand strategy in transplant IRVINE, Calif., August 8, 2024 (GLOBE NEWSWIRE) — Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published its second quarter 2024 results and the following letter to shareholders.

Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results

IRVINE, Calif., August 5, 2024 — Oncocyte Corp.

Oncocyte Announces August Investor Conferences Participation

Conference Call and Webcast on Thursday, August 8, 2024 at 2:00 p.m. PT / 5:00 p.m.

Oncocyte to Announce Second Quarter 2024 Financial Results on August 8

HOLLAND, Mich., July 11, 2024 – MedTech Gurus, a leading podcast focused on the forefront of medical technology, featured Oncocyte Corporation (NASDAQ: OCX) CEO Josh Riggs in its latest episode, “Take Advantage of the Moment.

MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in “Take Advantage of the Moment” Episode

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics company, Oncocyte's (Nasdaq: OCX) appointment of leading finance executive, Andrea James, as Chief Financial Officer. This strategic move comes at a pivotal time as Oncocyte prepares for significant commercial and regulatory milestones expected in 2024 and 2025.

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

IRVINE, Calif., June 17, 2024 – Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer.

Oncocyte Appoints Andrea James as Chief Financial Officer

New York, June 3, 2024—Oncocyte's (Nasdaq: OCX) VitaGraft Kidney™ diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published in the prestigious New England Journal of Medicine.

Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study

IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation  (Nasdaq: OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kidney was published in the New England Journal of Medicine . Oncocyte's Drs. Ekke Schuetz and Julia Beck, inventors of the technology, are among the authors of the study. VitaGraft Kidney was used to monitor graft injury in a phase 2 double-blind, placebo-controlled study ( NCT05021484 ) of the investigational drug felzartamab, a fully human CD38 monoclonal antibody, for antibody-mediated rejection (AMR), a leading cause of kidney allograft failure.

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

OncoCyte Corporation (NASDAQ:OCX ) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Jeff Ramson - Investor Relations Josh Riggs - President and Chief Executive Officer Conference Call Participants Mike Matson - Needham Mason Carrico - Stephens Operator Good afternoon. My name is Briana and I will be your conference operator today.

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

Conference Call on Wednesday, May 15, 2024, at 1:30 p.m. PT / 4:30 p.m.

ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS

IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation  (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024.

Oncocyte Reports First Quarter 2024 Financial Results

Conference Call and Webcast on Wednesday, May 15, 2024 at 1:30 p.m. PT / 4:30 p.m.

Oncocyte to Announce First Quarter 2024 Financial Results

Acrivon Therapeutics Inc

GrafTech International Ltd.

Liberty Media Corp-Liberty SiriusXM

Sirius XM Holdings Inc

UL Solutions Inc

At the end of the previous week, the Oracle of Omaha yet again boosted his stake in a media giant's tracking stocks, even with shares still in retreat.

Buffett Grabs More of This Stock, Plus Other Notable Insider Buying

OncoCyte Corporation (NASDAQ:OCX ) Q4 2023 Results Conference Call April 12, 2024 8:00 AM ET Company Participants Jeff Ramson - PCG Advisory Josh Riggs - President, CEO Conference Call Participants Mike Matson - Needham Mason Carrico - Stephens Bruce Jackson - Benchmark Company Operator Thank you for standing by. My name is JL, and I will be your conference operator today.

News for OncoCyte Stock (OCX)